Psoriasis Phototherapy: Coverage Barriers & Incentive Conflicts

For individuals navigating moderate to severe plaque psoriasis, treatment decisions often involve weighing effectiveness against cost and convenience. A recent simulation modeling study, published February 25, 2026, in JAMA Dermatology, sheds light on the comparative benefits and costs of biologics, phototherapy, and a step-therapy approach. The analysis, conducted between July 1 and November 21, 2025, suggests that while biologics offer the most significant gains in quality of life, step-therapy – initiating treatment with phototherapy and transitioning to biologics if insufficient improvement is seen – can achieve comparable benefits at a lower overall cost.

Understanding Psoriasis Treatment Options

Psoriasis is a chronic autoimmune disease that affects the skin, causing inflammation and scaling. Moderate to severe plaque psoriasis, characterized by raised, inflamed patches of skin, can significantly impact a patient’s quality of life. Treatment options range from topical creams and light therapy to systemic medications like biologics. Phototherapy, specifically ultraviolet (UV) light treatment, has long been a mainstay, but its accessibility can be limited by coverage policies and the need for frequent in-office visits. Biologics, are typically administered via injection or infusion and target specific parts of the immune system.

The study modeled outcomes for 500,000 simulated adult patients with a baseline Psoriasis Area and Severity Index (PASI) score of 20.2 (a measure of disease severity). PASI scores range from 0 (no disease) to 70 (very severe disease). Researchers used published estimates of efficacy, costs, and quality-adjusted life-years (QALYs) – a metric combining length and quality of life – from data spanning 2013 to 2025.

Efficacy and Variability Across Treatment Strategies

The simulation revealed notable differences in PASI reductions among the three treatment strategies. Biologics achieved a mean PASI reduction of 91.6%, while phototherapy resulted in a 71.1% reduction. The step-therapy regimen demonstrated the highest reduction, at 95.2%. However, the variability in PASI reductions was similarly significantly different. Phototherapy showed the most variability (30.3%), indicating a wider range of responses among patients, while step therapy exhibited the least (10.8%). This suggests that step therapy provides a more predictable outcome.

In terms of quality of life, biologics yielded the highest gains, with a mean QALY increase of 0.24. Phototherapy resulted in a 0.18 QALY gain, and step therapy offered 0.23 QALYs. While biologics showed the largest gains, the step-therapy approach came close, offering a substantial improvement in quality of life.

Cost Considerations and Payer Impact

The economic implications of each treatment strategy are substantial. The study focused on total treatment costs to payers (insurance companies, healthcare systems). The analysis found that step therapy offered a potential cost-saving benefit. While the study doesn’t provide specific dollar amounts, the findings suggest that initiating treatment with a more affordable option like phototherapy and reserving biologics for those who don’t respond can optimize resource allocation.

It’s important to note that the study focused on the payer’s perspective. Out-of-pocket costs for patients were considered a secondary outcome, but the analysis didn’t delve deeply into the financial burden on individuals. The research also considered risankizumab and adalimumab in sensitivity analyses, demonstrating the robustness of the findings across different biologic agents.

Phototherapy: A Closer Seem at the Options

Phototherapy encompasses several different types of ultraviolet (UV) light treatment. As the National Psoriasis Foundation explains, UVB and PUVA are the two main categories. UVB therapy, which is present in natural sunlight, slows the growth of affected skin cells. UVB treatment can be delivered through various methods, including broadband UVB, narrowband UVB (which uses a smaller range of UV light and may be more effective), excimer laser (targeting localized plaques), and home UVB phototherapy units. Narrowband UVB may clear psoriasis faster and produce longer remissions than broadband UVB, and may require fewer treatments per week.

Home phototherapy offers convenience and potential cost savings, but requires a consistent treatment schedule and initial setup at a medical facility. Excimer laser is particularly effective for scalp psoriasis, but long-term data on its durability is still emerging.

Limitations and Future Research

This simulation study relies on published estimates of efficacy and costs, which may not perfectly reflect real-world clinical practice. The model also doesn’t account for individual patient preferences, comorbidities, or potential adverse events. The data used in the analysis spanned 2013-2025, and treatment landscapes and costs may have shifted during that period.

Future research should focus on collecting real-world data on treatment outcomes and costs to validate these simulation findings. Studies should also explore patient-reported outcomes and preferences to better understand the factors that influence treatment decisions.

Implications for Clinical Practice and Policy

The study’s findings have implications for both clinical practice and healthcare policy. The results support the consideration of step-therapy strategies as a potentially cost-effective approach to psoriasis management. However, coverage policies and access to phototherapy remain significant barriers. Addressing these barriers could improve patient access to effective and affordable treatment options.

the optimal treatment strategy for psoriasis should be individualized, taking into account disease severity, patient preferences, cost considerations, and access to care. Ongoing monitoring and adjustments to treatment plans are essential to achieve the best possible outcomes.

What comes next: The findings from this study are likely to inform ongoing discussions among dermatologists, payers, and policymakers regarding optimal psoriasis treatment strategies. Further research, including prospective clinical trials evaluating the effectiveness and cost-effectiveness of step-therapy regimens, will be crucial to refine treatment guidelines and improve patient care.